Table 2. Univariate and Multivariate analysis for first CNS post alloHCT relapse.
| Variable | Total | Cohort 1 (n-110) (CNS Neg/CB Pos) |
Cohort 2 (n-33) (CNS Neg/CB Neg) |
P-value | 95% confidence interval | P-value | |
| Gender | Female | 39 | 28(25%) | 27(25%) | 0.330 | ||
| Male | 104 | 82(75%) | 82(75%) | ||||
| Age at transplantation | Age at trans < 18 | 71 | 43(38.5%) | 29(89%) | 0.0001 | ||
| Age at trans ≥ 18 | 71 | 67(61.5%) | 4(11%) | 3.59-45.84 | <0.0001 | ||
| ALL cell of origin (T-cell/B-cell) | B-ALL T-ALL |
100 36 |
70(63%) 30(37%) |
31(94%) 2(6%) |
0.001 | 1.64-104.36 | 0.0151 |
| Philadelphia chromosome | Positive | 35 | 33(28%) | 32(28%) | 0.242 | ||
| Negative | 101 | 77(72%) | 77(72%) | ||||
| Disease status prior to allo-HCT | CR1 CR≥2 |
69 73 |
59(52%) 52(48%) |
58(52%) 52(48%) |
0.358 | ||
| Stem Cell Source | Bone marrow | 9 | 8(7%) | 8(7%) | 0.613 | ||
| Cord blood | 6 | 4(4%) | 4(4%) | ||||
| Peripheral blood | 127 | 98(89%) | 97(89%) | ||||
| BMT year | 2007-2016 | 68 | 54(49%) | 53(49%) | 0.749 | ||
| 2017-2020 | 74 | 56(51%) | 56(51%) | ||||
| Thiotepa-containing Conditioning | No Yes |
140 2 |
107(98%) 3(2%) |
107(98%) 2(2%) |
1.000 | ||
| Risk stratification | Unknown risk | 46 | 38(35%) | 38(35%) | 0.084 | ||
| High risk | 41 | 35(31%) | 34(31%) | ||||
| Standard risk | 55 | 37(34%) | 37(34%) |